Ontozry (Cenobamate)

Cenobamate works by two complementary mechanisms: it selectively modulates voltage‑gated sodium channels, reducing neuronal hyper‑excitability, and it positively allosterically enhances GABA‑A receptor activity, increasing inhibitory signaling in the brain. This dual action contributes to seizure control.

The specific dose of Ontozry is individualized. A qualified prescriber determines the starting dose and titration schedule based on the patient’s clinical condition, response, and tolerability, following approved prescribing guidelines.

Safety data for cenobamate in pregnancy and lactation are limited. The drug should be avoided unless the potential benefit justifies the possible risk to the fetus or infant, and the decision should be made by a healthcare professional.

To request Ontozry, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with traditional sodium‑channel blockers such as carbamazepine, cenobamate offers additional GABA‑A receptor modulation, which may provide broader seizure control. Its efficacy as an add‑on therapy has been demonstrated in clinical trials, though individual response varies and safety profiles differ among agents.

Ontozry should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Ontozry is taken orally as a tablet. Patients should swallow the tablet whole with water, with or without food, as directed by their prescriber. Consistent daily dosing helps maintain stable drug levels.

Serious adverse events include drug reaction with eosinophilia and systemic symptoms (DRESS), severe skin reactions such as Stevens‑Johnson syndrome, significant hyponatremia, and marked elevations in liver enzymes. Prompt medical attention is required if any of these occur.

Patients with known hypersensitivity to cenobamate or any tablet excipients should avoid Ontozry. It is also contraindicated in individuals with severe hepatic impairment or those who have experienced serious skin reactions to related medications.